cariporide selective nah exchange inhibitor cariporide shown actively suppress cell death caused oxidative cariporide potent inhibitor may also useful treatment cariporide targets inhibits nah exchanger nhe isoform ubiquitously expressed involved ph regulation myocardial ischemia nhe activation leads influx na upon reperfusion reverses exchanger results overload intracellular inhibiting cariporide limits early influx na lends cardioprotective effect upon additionally cariporide slows normalization cellular ph following h efflux reperfusion triggered ischemiainduced hypothesized cariporide may also serve highly selective target anticancer therapy inhibition tumor cells see continuing following experimental research nheactivation effects myocardial injury cariporide proposed phase trial test whether inhibition nhe approves myocardial function patients undergoing percutaneous transluminal coronary angioplasty results trial published group individuals placed two trial groups first group given intravaneous bolus dose cariporide prior reperfusion second group given placebo days postinjection patients cariporide group showed number improvements placebo group trial proved nhe inhibition cariporide may effective way aid recovery acute coronary syndrome including heart attack unstable angina number one cause death america guard ischemia necrosis guardian trial conducted determine whether cariporide reduced incidence mortality myocardial infarction atrisk first largescale trial determine efficacy safety cariporide trial began may patients enrolled april total investigative sites chosen countries totaling patients patients split four study groups placebo mg doses infusions three times primary goals guardian trial assess rate death myocardial infarction day four trial groups largescale safety side effects associated cariporide results showed doses statistically similar placebo group group showed relative risk reduction similar mortality cariporide showed efficacy certain subgroups patients varying drug concentrations overall guardian trial showed cariporide significantly reduce patient risk myocardial infarction despite result cariporide showed promise postcoronary artery bypass grafting cabg subgroup reduction postsurgery mortality mi suggesting highdoses prolonged releases cariporide may efficacious highrisk sodiumproton exchange inhibition prevent coronary events acute cardiac conditions expedition trial phase iii trial assess efficacy safety cariporide patients received cabg surgery patients accepted july july placed two trial groups first group received consecutive dosing regimen detailed table second group received placebo results trial showed statistically significant decline mortality myocardial infarction however looked individually rate myocardial infarction declined mortality increased due increase mortality cariporide pass clinical however studies showed first time inhibition nhe affords protection myocardium research decoupling adverse effects mortality protective effects clinical trials cariporide given intravenous injection early clinical trials see phase showed significant improvements placebo dose prior arterial phase iii clinical trials cariporide conclude highly dosedependent earlier trials showed high doses cariporide three times daily may increase efficacy expedition trial found increased rate mortality associated higher largest clinical trial cariporide found significant adverse effects cariporide patients see phase iii guardian however later clinical trial found dosedependent increases mortality patients using cariporide postcabg see phase iii expedition since findings expedition trial research cariporide slowed increased risk mortality associated high concentrations lack efficacy low concentration make unlikely cariporide reach market cardioprotective agent ischaemia reperfusion however recent research conducted cariporide anticancer treatment inhibition cariporide may provide mechanism initiating internal acidification cancer cells leading cancer cells utilize unique mechanism providing high intracellular ph low extracellular ph preventing internal acidification leading efflux h tumor first patent pertaining cariporide use submitted march antiarrhythmic agent granted january since multiple patents issued use delivery investigation cariporide however drug approved marketed cariporide httpsenwikipediaorgwikicariporide